Search This Blog

Tuesday, September 29, 2020

InflaRx up on encouraging data on lead drug in COVID-19

InflaRx (IFRX +12.7%) jumps on a 5x surge in volume in apparent reaction to results from the first portion of a Phase 2/3 clinical trial, PANAMO, in the Netherlands evaluating lead candide IFX-1 plus best supportive care (BSC) in severely ill hospitalized adult COVID-19 patients. The data were just published in The Lancet Rheumatology.

Patients receiving IFX-1 plus BSC experienced a 24% relative improvement in blood oxygenation, measured by the mean PaO2/FiO2 ratio (arterial oxygen partial pressure/fractional inspired oxygen), versus BSC and a 14% relative mortality benefit at day 28.

The safety profiles were similar.

The Phase 3 portion launched two weeks ago.

In June, shares briefly sold off on preliminary data that showed no difference in between IFX-1 and BSC in the oxygenation index.

IFX-1 is a monoclonal anti-human complement factor C5a antibody designed to induce an anti-inflammatory response by blocking the biological activity of C5a.

https://seekingalpha.com/news/3618129-inflarx-up-13-on-encouraging-data-on-lead-drug-in-covidminus-19

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.